



Strategic Alliances, Joint Ventures and Licensing

2009-2010: Market leaders in life sciences, technology, financial services, communications

and many other industries turn to WilmerHale for legal advice and business advantage. In 2009,

our corporate, licensing, intellectual property and regulatory lawyers handled more than 100

licensing, strategic alliance, collaboration, joint venture, product development, outsourcing,

manufacturing, distribution and similar agreements, including deals that are helping to shape

the future of science and technology. In recent years, we have advised clients throughout the

United States and Europe on strategic alliances that have received industry recognition for their

importance, and our lawyers have been recognized as global leaders in this field.



Counsel of Choice for Strategic Alliances, Joint Ventures and Licensing

SERVING INDUSTRY LEADERS IN TECHNOLOGY, LIFE SCIENCES, CLEANTECH, FINANCIAL SERVICES, COMMUNICATIONS AND BEYOND

 <p>License from Cystic Fibrosis Foundation to Liprotamase</p>	 <p>License for Calando's oncology drug delivery technology</p>	 <p>Drug development licensing matters</p>	 <p>Advice in connection with technology transactions</p>	 <p>Collaboration with Cubist to develop novel ion channel pain drugs</p>	 <p>Drug development collaborations with Novartis and Eli Lilly</p>	 <p>Various data licensing and distribution matters</p>	 <p>License agreements for advanced power cell technology</p>
 <p>Various licensing matters</p>	 <p>Collaboration with Sanofi-Aventis for Wellstat's oral insulin sensitizer for type 2 diabetes</p>	 <p>Collaboration with GSK for the development of novel deuterium-modified drugs</p>	 <p>Distribution and licensing of security devices</p>	 <p>Advice in connection with NHL Center Ice broadcast package</p>	 <p>Worldwide license of HIV treatment to GSK</p>	 <p>Various video game licensing and distribution matters</p>	 <p>Research and development collaboration with Novartis</p>
 <p>Collaboration with Roche for discovery and development of RNAi therapeutic products</p>	 <p>Spinout and formation of the Broad Institute for Biomedical Research</p>	 <p>Strategic relationship with Bank of America for electronic payment and invoice network</p>	 <p>License to Biogen Idec of ex-US rights to fampridine</p>	 <p>Joint development agreement with NEC for data warehouse appliances</p>	 <p>Oncology drug discovery and translational research collaboration with OSI Pharmaceuticals</p>	 <p>Various licensing and collaboration matters</p>	 <p>Collaboration with Sanofi-Aventis for oncology antibody drugs</p>
 <p>Research and exclusive license agreement with Teva</p>	 <p>Worldwide license from Pfizer for ApoA-I Milano coronary treatment</p>	 <p>Alliance with Roche for inflammation drugs</p>	 <p>Collaboration with Seattle Genetics for oncology antibody drugs</p>	 <p>Drug development and commercialization agreements</p>	 <p>Licensing of solar technology and sale of related equipment</p>	 <p>Licensing and acquisition option agreement with Alcon for Potentia's ophthalmic business</p>	 <p>Drug discovery collaborations with Roche and Celgene</p>



Mixed Sources
 Product group from well-managed
 forests, controlled sources and
 recycled wood or fiber
 www.fsc.org Cert no. BV-COC-070904
 © 1996 Forest Stewardship Council

WilmerHale recognizes its corporate responsibility to environmental stewardship.



wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers regulated by the Solicitors Regulation Authority (SRA No. 287488). In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. This material is for general informational purposes only and does not represent our legal advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all relevant legal developments. Prior results do not guarantee a similar outcome. © 2010 Wilmer Cutler Pickering Hale and Dorr LLP